Showing 6011-6020 of 9662 results for "".
Hoya ConBio - Laser Assisted Hair Reduction
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/hoya-conbio-laser-assisted-hair-reduction/19461/Video demonstrations on the different settings to use for laser assisted hair reduction.The Importance of the Atopic Dermatitis Pipeline
https://practicaldermatology.com/videos/dermatology-hub-neuroimmune-network/derm-hub/37148/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, a board-certified dermatologist in San Diego, California, and Director of Clinical Dermatology at Therapeutics Clinical Research, provides an overview of important research underway involving new therapeutics for the treatment of atopDWTV Extra: Vitiligo Ingenuity Award
https://practicaldermatology.com/videos/dermwire-tv/dwtv-extra-vitiligo-ingenuity-award/37869/Hannah Metheny, a student at the University of Miami Miller School of Medicine, discusses winning an Incyte Ingenuity Award in Vitiligo for the "Barriers and Facilitators to Psychosocial Support as an Integral Aspect of Vitiligo Patient Comprehensive Care" project.DWTV Extra: GPP Awareness Day
https://practicaldermatology.com/videos/dermwire-tv/dwtv-extra-gpp-awareness-day/36704/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, discusses the importance of educating more clinicians about generalized pustular psoriasis (GPP) and observing GPP Awareness Day on August 13.Nemluvio Shows Efficacy in AD
https://practicaldermatology.com/videos/dermwire-tv/nemluvio-shows-efficacy-in-ad/36134/In this episode of DermwireTV, Nemluvio (nemolizumab) showed efficacy in atopic dermatitis in recent studies; strontium cream helps manage pruritus in hidradenitis suppurativa (HS); and Lisa Swanson and Peter Lio get viewers up to date on dupilumab’s effectiveness at halting atopic march.All Things Psoriasis With Dr. April Armstrong
https://practicaldermatology.com/podcasts/practical-dermatology-podcasts/all-things-psoriasis-with-dr-april-armstrong/36135/The latest news and updates, plus April W. Armstrong, MD, MPH, joins Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, to discuss the current state of psoriasis treatments, what's in the pipeline, her experience in leadership positions for multiple psoriasis organizations, and more.Analyzing Safety Data From Level Up
https://practicaldermatology.com/podcasts/practical-dermatology-podcasts/analyzing-safety-data-from-level-up/33944/The latest news and updates, plus Matthew Zirwas, MD, FAAD, joins Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, to discuss the importance of the Week 16 safety data from the Level Up study on upadacitinib. Silverberg JI, Bunick CG, et al. Efficacy and safety of upadacitinib versuThe Impact of Clascoterone Topical Cream, 1%: The US Experience 4 Years After Approval and Clinical Expectations for Acne Patients in Other Regions of the World
https://practicaldermatology.com/topics/acne-rosacea/Impact-Clascoterone-Topical-Cream/32830/Clascoterone topical cream, 1% (Winlevi), approved by the US Food and Drug Administration (FDA) in 2020 as the first novel drug introduced for the treatment of acne vulgaris since 1982, is indicated in the US for patients 12 years of age and older. The safety and efficacy were supported by two succeAnalysis Evaluates Risks of Cardiovascular Events Among Biologics for Psoriatic Diseases
https://practicaldermatology.com/videos/dermwire-tv/analysis-evaluates-risks-of-cardiovascular-events-among-biologics-for-psoriatic-diseases/32412/In this week's DermwireTV, a new analysis evaluates the risks of major adverse cardiovascular events among patients treated with biologics for psoriatic diseases; a phase 3 clinical trial examines the use of nemolizumab in adults with prurigo nodularis; and the president of Journey Medical discussesFDA Approves Bimzelx for Hidradenitis Suppurativa
https://practicaldermatology.com/videos/dermwire-tv/fda-approves-bimzelx-hidradenitis-suppurativa/29518/In this week's DermwireTV, the FDA approves a new treatment for moderate to severe hidradenitis suppurativa; the FDA agrees to review the resubmission of Dupixent for the treatment of CSU; and the president of Merz Aesthetics, North America, joins us to discuss trends in the aesthetic market.